Comparable stake leader
NEW ENTERPRISE ASSOCIATES 13 LP
SEC ownership of PhaseBio Pharmaceuticals Inc
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001169245.
Disclosed value leader
—
Comparable rows
0/15
Latest evidence
19 May 2023
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
NEW ENTERPRISE ASSOCIATES 13 LP
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
19 May 2023
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001169245
- Issuer location
- Malvern, PA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of PhaseBio Pharmaceuticals Inc (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
NEW ENTERPRISE ASSOCIATES...
Disclosed value leader
—
Comparable rows
0/15
Latest evidence
19 May 2023
3/4/5
Some rows are evidence-backed but not safely comparable across classes.
15 rows are not safely comparable across share classes.
Showing 1-8 of 15 holder rows.
Quick read
SEC ownership evidence is available, but the rows are not safely comparable across share classes.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens NEW ENTERPRISE ASSOCIATES 13 LP's linked filing trail.
Detailed SEC evidence table Showing 1-8 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| NEW ENTERPRISE ASSOCIATES 13 LP |
3/4/5
10%+ Owner
|
—
class O/S missing
|
—
4,857,525 shares
|
— | 25 Oct 2022 |
| Clay Thorp |
3/4/5
Director
|
—
class O/S missing
|
—
3,581,733 shares
|
— | 19 May 2023 |
| Jonathan P. Mow |
3/4/5
Chief Executive Officer, Director
|
—
class O/S missing
|
—
183,701 shares
|
— | 20 May 2022 |
| John Sang Lee |
3/4/5
Chief Medical Officer
|
—
mixed-class rows
|
—
140,250 shares
mixed-class rows
|
— | 24 Feb 2022 |
| John P. Sharp |
3/4/5
Chief Financial Officer
|
—
class O/S missing
|
—
65,767 shares
|
— | 20 May 2022 |
| Nancy J. Hutson |
3/4/5
Director
|
—
class O/S missing
|
—
41,510 shares
|
— | 19 May 2023 |
| Susan Elizabeth Arnold |
3/4/5
SVP, Technical Operations
|
—
class O/S missing
|
—
41,236 shares
|
— | 20 May 2022 |
| Jonathan Birchall |
3/4/5
Chief Commercial Officer
|
—
class O/S missing
|
—
20,000 shares
|
— | 20 May 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 10 Jul 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to PhaseBio Pharmaceuticals Inc. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
NEW ENTERPRISE ASSOCIATES 13 LP
Net 12M change
$0
Latest report
19 May 2023
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| NEW ENTERPRISE ASSOCIATES 13 LP | 10%+ Owner | Mixed | 25 Oct 2022 | |||
| Peter Justin Klein | Director | Mixed | 03 Jun 2021 | |||
| William D. Humphries | Director | Mixed | 19 May 2023 | |||
| John P. Sharp | Chief Financial Officer | Mixed | 20 May 2022 | |||
| Jonathan P. Mow | Chief Executive Officer, Director | Mixed | 20 May 2022 | |||
| Glen Burkhardt | SVP of Human Resources | Mixed | 20 May 2022 | |||
| Nancy J. Hutson | Director | Mixed | 19 May 2023 | |||
| Clay Thorp | Director | Mixed | 19 May 2023 | |||
| Alex Sapir | Director | Mixed | 19 May 2023 | |||
| Richard van den Broek | Director | Mixed | 19 May 2023 | |||
| Jonathan Birchall | Chief Commercial Officer | Mixed | 20 May 2022 | |||
| John Sang Lee | Chief Medical Officer | Mixed | 24 Feb 2022 | |||
| Caroline M. Loewy | Director | Mixed | 19 May 2023 | |||
| Edmund Harrigan | Director | Mixed | 19 May 2023 | |||
| Michael York | VP, Corporate Development | Mixed | 20 May 2021 | |||
| Kristopher L. Hanson | SVP and General Counsel | Mixed | 20 May 2022 | |||
| Susan Elizabeth Arnold | SVP, Technical Operations | Mixed | 20 May 2022 |
Recent insider transactions for PhaseBio Pharmaceuticals Inc
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.